A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies.

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

February 9, 2027

Study Completion Date

June 22, 2027

Conditions
Systemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
Interventions
DRUG

AZD5492

IMP: subcutaneous.

Trial Locations (29)

2333

WITHDRAWN

Research Site, Leiden

31059

RECRUITING

Research Site, Toulouse

33000

NOT_YET_RECRUITING

Research Site, Bordeaux

34295

NOT_YET_RECRUITING

Research Site, Montpellier

36207

RECRUITING

Research Site, Anniston

39120

NOT_YET_RECRUITING

Research Site, Magdeburg

41010

RECRUITING

Research Site, Seville

47012

RECRUITING

Research Site, Valladolid

50937

NOT_YET_RECRUITING

Research Site, Cologne

54035

NOT_YET_RECRUITING

Research Site, Nancy

67098

NOT_YET_RECRUITING

Research Site, Strasbourg

75013

NOT_YET_RECRUITING

Research Site, Paris

91054

NOT_YET_RECRUITING

Research Site, Erlangen

100730

NOT_YET_RECRUITING

Research Site, Beijing

200001

NOT_YET_RECRUITING

Research Site, Shanghai

430022

NOT_YET_RECRUITING

Research Site, Wuhan

L8S 4K1

NOT_YET_RECRUITING

Research Site, Hamilton

J1G 2E8

NOT_YET_RECRUITING

Research Site, Sherbrooke

113-8655

NOT_YET_RECRUITING

Research Site, Bunkyō City

761-0793

NOT_YET_RECRUITING

Research Site, Kita-gun

807-8555

NOT_YET_RECRUITING

Research Site, Kitakyushu-shi

606-8501

NOT_YET_RECRUITING

Research Site, Kyoto

852-8501

NOT_YET_RECRUITING

Research Site, Nagasaki

1105 AZ

NOT_YET_RECRUITING

Research Site, Amsterdam

06800

RECRUITING

Research Site, Mérida

G31 2ER

RECRUITING

Research Site, Glasgow

SE5 9RS

RECRUITING

Research Site, London

WC1E 6JF

RECRUITING

Research Site, London

SO16 6YD

RECRUITING

Research Site, Southampton

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Fortrea

INDUSTRY

lead

AstraZeneca

INDUSTRY